Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
22 mars 2021 16h08 HE
|
Kura Oncology, Inc.
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC – – Statistically significant improvement in median PFS...